This table lists all the major pharma collaborations, acquisitions and mergers agreed during January 2014.
For an indepth analysis of these deals, read ‘Pharma deals during January 2014’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Edison Pharmaceuticals/ Dainippon Sumitomo Pharma | Strategic alliance | Extends development/ commercialisation* agreement to EPI 743 and EPI 589 for mitochondrial disease, includes stock purchase and 10 further NCEs | 4,295 |
| Aptalis/ Forest | Company acquisition | Acquiring sales turnover of $688m | 2,900 |
| Alnylam/ Genzyme | Extended agreement | Additional markets for patisiran and 3 pipeline products with option to all rare disease products | 700 |
| Biogen Idec/ Royalty Pharma | Earn out | Indirect interest in Tecfidera sales in Germany in relapsing forms of MS | 510 |
| JHP/ Par Pharmaceuticals | Company acquisition | Par acquires JHP, a leading specialty pharmaceutical company of branded and generic sterile injectables | 490 |
| Aerial BioPharma/ Jazz Pharmaceuticals | Product rights | Jazz gain access to ADX N05 for treatment of narcolepsy, SK Biopharmaceuticals retain some Asian rights, upfront of $125m, Aerial and SK receive milestones and royalties | 397 |
| Scientific Protein Labs/Shenzhen Hepalink | Company acquisition | API supplier | 337.5 |
| Capricor Therapeutics/ Janssen Biotech | Collaboration and exclusive licence option | CAP1002 an allogeneic cardiosphere-derived cell (CDC) therapeutic for treatment of myocardial infarction | 337.5 |
| Immunocore/AZ Medimmune | Collaboration and licence | Immune mobilising monoclonal T-Cell receptor against cancer (ImmTAC) therapies | 320 |
| Sangamo/Biogen Idec | Collaboration and licence | Development of therapies for haemoglobinopathies using zinc finger genome editing | 320 |
| Shire/ Organogenesis | Divestment | Shire’s sale of its Dermagraft assets acquired as part of Advanced BioHealing | 300 |
| Merck/Alnylam | Divestment | Sale of Merck’s RNAi therapeutics unit Sirna | 290 |
| Santaris/Roche | Discovery and development | Novel RNA targeted medicines using Santaris’ locked nucleic acid drug platform | 148 |
| NuPathe/ Teva | Company acquisition | Includes key product Zecuity [sumatriptan] for migraine | 144** |
| Moderna Therapeutics/ Alexion Pharmaceuticals | Exclusive discovery and development | Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options | 100 |
| Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma | Exclusive licensing agreement for Europe and Japan | The combination of CPP-1X/sulindac for the treatment of familial adenomatous polyposis (FAP an orphan disease) | 100+ |
| ACT Biotech/ Eddingpharm | Acquisition | Acquisition of 3 small molecule assets: Telatinib, a p3 ready VEGFr inhibitor for gastric cancer, ACTB1003, ACTB1010 (both p1 ready) | 95 |
| Horizon/ AZ | Collaboration and licence | Screening using siRNA platform for oncology drug targets | 88 |
| NantBioScience/ Celgene | Licence and option agreement | Nab [nanoparticle albumin bound] technology, option to protein kinases drug candidates, NTB-010, NTB-011 | 75 |
| Living Proof/ Valeant | Development and commercialisation | Aesthetic dermatology products | 75 |
*JP and N. America
**Further payments are due if Zecuity sales exceed a given threshold.